BiotechTube

IV Loop Diuretics (LD)

Pre-clinicalTerminated
2 views this week 0 watching💤 Quiet
Interest: 8/100
8
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Heart Failure

Conditions

Heart Failure, Cardiac Failure, Acute Decompensated Heart Failure (ADHF)

Trial Timeline

Jan 1, 2012 → Jul 1, 2014

NCT ID
NCT01474200

About IV Loop Diuretics (LD)

IV Loop Diuretics (LD) is a pre-clinical stage product being developed by Nuwellis for Heart Failure. The current trial status is terminated. This product is registered under clinical trial identifier NCT01474200. Target conditions include Heart Failure, Cardiac Failure, Acute Decompensated Heart Failure (ADHF).

What happened to similar drugs?

20 of 20 similar drugs in Heart Failure were approved

Approved (20) Terminated (2) Active (0)
✅SGLT2i, beta blocker, ARNI, MRA, MTDEli LillyApproved
✅Prasugrel 10 mg daily x 2 weeks + Clopidogrel 75 mg daily x 2 weeksDaiichi SankyoApproved
✅ConivaptanAstellas PharmaApproved
✅RegadenosonAstellas PharmaApproved
✅Regadenoson + GadoliniumAstellas PharmaApproved
✅regadenosonAstellas PharmaApproved
✅Tacrolimus granules + Tacrolimus capsulesAstellas PharmaApproved

Hype Score Breakdown

Clinical
3
Activity
0
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01474200Pre-clinicalTerminated

Competing Products

20 competing products in Heart Failure

See all competitors
ProductCompanyStageHype Score
mRNA-0184ModernaPhase 1
0
IV diureticNuwellisPre-clinical
16
IV Loop DiureticsNuwellisPre-clinical
23
Stepped pharmacologic careNuwellisPhase 3
30
TRV120027 + Normal SalineTrevenaPhase 1
19
TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + PlaceboTrevenaPhase 2
25
TRV120027 + PlaceboTrevenaPhase 1/2
22
Ilofotase alfa + PlaceboAM-PharmaPhase 2
25
INXN-4001PrecigenPhase 1
23
LY3461767 + PlaceboEli LillyPhase 1
29
SGLT2i, beta blocker, ARNI, MRA, MTDEli LillyApproved
43
Pactimibe, CS-505Daiichi SankyoPhase 2
35
Prasugrel 10 mg daily x 2 weeks + Clopidogrel 75 mg daily x 2 weeksDaiichi SankyoApproved
43
olmesartan medoxomil + candesartan cilexetil placebo + olmesartan medoxomil placebo + candesartan cilexetilDaiichi SankyoPhase 3
32
OlmesartanDaiichi SankyoPhase 3
40
Carperitide + PlaceboDaiichi SankyoPhase 2
35
EdoxabanDaiichi SankyoPre-clinical
22
RegadenosonAstellas PharmaPhase 1
29
Advagraf + PrografAstellas PharmaPhase 2
35
FK506EAstellas PharmaPhase 3
40